Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism ...
Immuneering is developing atebimetinib, a novel MEK inhibitor, in multiple solid tumors, having already produced impressive phase 2a data in pancreatic cancer. IMRX's near-term catalyst is the January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results